An artificial double tandem tumor-specific promoter based on survivin and human telomerase reverse transcriptase gene promoters was constructed. Studies in in vitro and ex vivo therapeutic systems showed that the designed promoter exhibits a high activity in tumor cells, which is comparable to the activity of the CMV constitutive promoter.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1134/S1607672918030092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma.
J Immunother Cancer
November 2024
NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
Article Synopsis
- Nasopharyngeal carcinoma (NPC) is a common type of head and neck cancer found mainly in southern China and Southeast Asia, characterized by persistent activation of interferon signaling and weakened T cell immunity.
- The study used RNA sequencing to show that FOXA1, a pioneer factor, suppresses the interferon signaling pathway and PD-L1 expression in NPC cells, impacting T cell responses and apoptosis.
- Loss of FOXA1 in NPC cells leads to increased IFN signaling activation and T cell dysfunction, indicating that FOXA1 plays a crucial role in regulating immune responses against NPC.
Intelligent Modular DNA Lysosome-Targeting Chimera Nanodevice for Precision Tumor Therapy.
J Am Chem Soc
October 2024
State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), National Synergetic Innovation Center for Advanced Materials (SICAM), Nanjing University of Posts and Telecommunications, 9 Wenyuan Road, Nanjing 210023, China.
Lysosome targeting chimeras (LYTACs) have emerged as a powerful modality that can eliminate traditionally undruggable extracellular tumor-related pathogenic proteins, but their low bioavailability and nonspecific distribution significantly restrict their efficacy in precision tumor therapy. Developing a LYTAC system that can selectively target tumor tissues and enable a modular design is crucial but challenging. We here report a programmable nanoplatform for tumor-specific degradation of multipathogenic proteins using an intelligent modular DNA LYTAC (IMTAC) nanodevice.
View Article and Find Full Text PDFMenin in Cancer.
Genes (Basel)
September 2024
Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Article Synopsis
- Menin, a protein encoded by a specific gene, acts as a nuclear scaffold that regulates gene expression by interacting with chromatin modifiers and transcription factors.
- Its role in cancer is complex, as it can function as both a tumor suppressor in conditions like MEN1 syndrome and cholangiocarcinoma, and as a tumor promoter in various other cancers like leukemia and colorectal cancer, depending on the type and context of the tumor.
- The review focuses on the diverse roles of menin across different cancer types, emphasizing the need for further research to understand its mechanisms and therapeutic potential.
Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression.
J Physiol Biochem
November 2024
Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, 3008, Pamplona, Spain.
DNA methylation is crucial for chromatin structure, transcription regulation and genome stability, defining cellular identity. Aberrant hypermethylation of CpG-rich regions is common in cancer, influencing gene expression. However, the specific contributions of individual epigenetic modifications to tumorigenesis remain under investigation.
View Article and Find Full Text PDFEstrogen-related receptor alpha promotes thyroid tumor cell survival via a tumor subtype-specific regulation of target gene networks.
Oncogene
July 2024
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Mortalin (encoded by HSPA9) is a mitochondrial chaperone often overexpressed in cancer through as-yet-unknown mechanisms. By searching different RNA-sequencing datasets, we found that ESRRA is a transcription factor highly correlated with HSPA9 in thyroid cancer, especially in follicular, but not C cell-originated, tumors. Consistent with this correlation, ESRRA depletion decreased mortalin expression only in follicular thyroid tumor cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!